Scientists at St. Jude Children’s Research Hospital have revealed how Fanzor2’s divergence from bacterial ancestors may make it a useful tool for future genomic engineering endeavors.
Structure of a eukaryotic CRISPR-Cas homolog, Fanzor2, shows promise for gene editing
